June 11, 2020 / 10:23 PM / a month ago

BRIEF-Viela Bio Announces U.S. FDA Approval Of Uplizna (Inebilizumab-Cdon) For Treatment Of Neuromyelitis Optica Spectrum Disorder

June 11 (Reuters) - Viela Bio Inc:

* VIELA BIO ANNOUNCES U.S. FDA APPROVAL OF UPLIZNA™ (INEBILIZUMAB-CDON) FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

* VIELA BIO INC - ANTICIPATES PRODUCT LAUNCH IN JUNE. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below